A Study of Ramucirumab or Icrucumab in Colorectal Cancer
Status:
Completed
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if participants with metastatic colorectal cancer
live longer without their cancer progressing when treated with standard chemotherapy,
standard chemotherapy plus ramucirumab, or standard chemotherapy plus icrucumab.